Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT ID: NCT07159750
Last Updated: 2025-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
700 participants
OBSERVATIONAL
2024-01-02
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment
NCT03481400
Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
NCT06459648
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
NCT03777059
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
NCT05281770
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Migraine Patients
Migraine patients who initiate a CGRP-targeted treatment
CGRP antibody or gepant
Patients will start anti-CGRP or its receptor antibody or gepants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CGRP antibody or gepant
Patients will start anti-CGRP or its receptor antibody or gepants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
* Signature of informed consent.
Exclusion Criteria
* Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitari Vall d'Hebron Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patricia Pozo-Rosich, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Vall d'Hebron University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami, Miller School of Medicine
Miami, Florida, United States
FLENI
Buenos Aires, , Argentina
Pontificia Universidad Católica de Chile
Santiago, , Chile
Neuromedica
Medellín, , Colombia
Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno
Rovinj, , Croatia
Charité Universitätsmedizin Berlin
Berlin, , Germany
LMU University Hospital
München, , Germany
University of L'Aquila
L’Aquila, , Italy
University of Modena and Reggio Emilia
Modena, , Italy
National Neurological Institute C. Mondino Foundation
Pavia, , Italy
IRCCS San Raffaele
Roma, , Italy
Universiti Putra Malaysia
Serdang, Selangor, Malaysia
Neuroclinic Norway
Lillestrøm, , Norway
Wrocław Medical University
Wroclaw, , Poland
Hospital Santa Maria Lisbon
Lisbon, , Portugal
Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain
Vall d'Hebron University Hospital
Barcelona, Barcelona, Spain
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Fundació Sanitària Mollet
Mollet del Vallès, Barcelona, Spain
Hospital de Viladecans
Viladecans, Barcelona, Spain
Hospital General Universitario de Albacete
Albacete, , Spain
Fundación Jiménez Díaz
Madrid, , Spain
Hospital Universitario Gregorio Marañón
Madrid, , Spain
La Paz University Hospital
Madrid, , Spain
Hospital Clínico Universitario Lozano Blesa
Zaragoza, , Spain
Mersin University
Mersin, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EOM(AG)008/2024(6234)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.